Document is current
Any future updates will be listed below
-
Authors
Guedjdal, Sarah
Leghay, Coline
Derisbourg, Maxime
Eddarkaoui, Sabiha
Lecerf, Simon
Vermon, Florian
Caillierez, Raphaelle
Begard, Séverine
Regost, Claire
Laloux, Charlotte
da Costa, Paulo J.
Carvalho, Kevin
Chiappetta, Giovanni
Verdier, Yann
Buée-Scherrer, Valérie
Deramecourt, Vincent
Schraen, Susanna
Blum, David
Martin, Franck
Buée, Luc
Hamdane, Malika
-
Funding
Funding for this research was provided by:
Fondation pour la Recherche Médicale (ALZ201912009641)
Agence Nationale de la Recherche (LabEx DISTALZ ANR-11-LABX-01)
Agence Nationale de la Recherche (RiboTAUxic ANR-21-CE12-0028-01)
Association France Alzheimer (AAP PFA 2024 - Dossier #6469)
Inserm Transfert (MAT-PI-14188-A-01)
Inserm Transfert (MAT-PI-18399-A-03)
Conseil Régional Hauts-de-France (Start-AIRR 2016-06656)
- License Information
-
More Information
Article History
Received: 21 October 2025
Accepted: 13 March 2026
First Online: 27 April 2026
Declarations
:
: The Human brain tissue samples were obtained from The Lille NeuroBank collection. The Lille NeuroBank has been declared to the French Research Ministry by the Lille University Hospital (CHU-Lille) on August 14, 2008 under the reference DC-2000-642 and fulfills the criteria defined by French Law regarding biological resources, including informed consent; ethics review committee approval and data protection. The ethical review committee of Lille NeuroBank approved the study. All the experimental protocols involving mice were approved by the CEEA75 ethical committee (12787-2015101320441671v9) .
:
: LB, MH, DB, MD, CLe, GC, YV are inventors of the patent “WO2018178078A1”: New tau species (2018). MH, LB, DB, SE, SG are inventors of the patent “WO2020193520A1”: Treatment of tauopathy disorders by targeting new tau species (2020). These 2 patents are related to antibodies targeting AcMet11-Tau species. The remaining authors declare that they have no competing interests.
